It has been shown recently that expression of p21 is enhanced by paclitaxel. This cytotoxic compound induces mitotic spindle damage resulting in blockade of the mitotic cell cycle associated or not with apoptotic cell death. In the present study, we showed that, in MCF-7 cells, paclitaxel induced accumulation of p21 in cells with a G2/M DNA content, corresponding to cells either in abnormal mitosis or in an interphase-like state (decondensed chromatin) with multiple nuclei. In MCF-7 cells, the increase in p21 was subsequent to the mitotic arrest and was associated with the exit from abnormal mitosis leading to formation of cells with micronuclei. In this cell line, we noted a relationship between the elevation of p21 expression and the inhibition of p34 cdc2 activity. High levels of p21 protein were also found to be associated with inactive p34 cdc2 /cyclin B protein complex after treatment with paclitaxel. Treatment with p21 antisense oligonucleotide partially blocked induction of p21 expression by paclitaxel and signi®cantly reduced survival of MCF-7 cells exposed to this agent. In NIH-OVCAR-3 cells, which are de®cient in basal and paclitaxel-induced p21 expression, paclitaxel led to a prolonged activation of p34 cdc2 and a delayed mitotic exit associated with apoptotic cell death. These observations suggest that p21 is not required for the mitotic arrest in response to paclitaxel, but argue in favor of a role for this inhibitor in facilitating the exit from abnormal mitosis. This eectively enhances cell survival after paclitaxel-induced spindle damage.
Introduction
Cell cycle progression is regulated by cyclin-dependent kinases (Cdks) counterbalanced by cdk inhibitors (CKIs). p21, a potent inhibitor of cdk2 and cdk4, is responsible for G1/S arrest induced by p53 in response to DNA damage (El-Deiry et al., 1993; Dulic et al., 1994) . p21 may inhibit cell cycle progression not only by inhibiting cdk activity but also by binding directly to the proliferating cell nuclear antigen (PCNA) (Waga et al., 1994) . p21 is also induced by p53 independent pathways during cell senescence (Noda et al., 1994) , cell dierentiation (Jiang et al., 1994; Steinman et al., 1994) , as well as during the transition from quiescence to proliferation after addition of growth factors (Macleod et al., 1995) . The expression of p21 is regulated during the cell cycle. p21 mRNA reaches a peak immediately after serum stimulation of quiescent cells, decreases at the G1/S transition, falls to a nadir in the S phase and then reaccumulates during the G2 and M phases of the cell cycle (Li et al., 1994) . Expression of p21 in the G2/M phase of the cell cycle raises the question of the role of p21 in the control of the cell cycle during these particular phases.
The cytotoxic eect of paclitaxel stems from its ability to stabilize microtubules and promote microtubule assembly (Schi et al., 1979 (Schi et al., , 1980 . The eect of paclitaxel on microtubule dynamics has been thought to account for the cell cycle block in mitosis (Rowinsky et al., 1988) resulting in apoptotic cell death in certain cell types (Bhalla et al., 1993; Tang et al., 1994) . Paclitaxel also blocks cell cycle progression in G1, but only in normal cells (Wahl et al., 1996; Trielli et al., 1996) . Furthermore, the ability of normal cells to arrest in G1 after treatment with paclitaxel may account for their resistance to the cytotoxicity of this agent (Wahl et al., 1996; Trielli et al., 1996) . A role for p53 in resistance of normal cells to paclitaxel has been recently demonstrated. p53 facilitates the progression of normal cells through mitosis (Cross et al., 1995) and enables them to arrest in the G1 phase of the cell cycle (Wahl et al., 1996) . An association between induction of p21 and G1 arrest following paclitaxel treatment has been shown in human foreskin ®broblasts (Wahl et al., 1996) , but not in rat primary ®broblasts (Trielli et al., 1996) . Although tumoral cells may escape the G1 block induced by paclitaxel, it has recently been shown that paclitaxel induces accumulation of p21 in both p53 wild-type and p53-null cancer cells (Blagosklonny et al., 1995) . In an attempt to determine the role of p21 in the response of tumoral cells to paclitaxel, we tested its action on two dierent adenocarcinoma cell lines, MCF-7 and NIH-OVCAR-3, which are both sensitive to paclitaxel. Whereas p21 has been found to play a role in the growth arrest of MCF-7 cells following exposure to substances such as TGF-b1 and PGA 2 (Gorospe et al., 1996b) , we noted that p21 is not expressed at the basal level in NIH-OVCAR-3 cells . The results of the present study on the two cell lines show that p21 is not required for the paclitaxel-induced arrest of the cell cycle in mitosis, but argue in favor of a role for p21 in the exit from abnormal mitosis. Treatment with antisense p21 oligonucleotide reduced cell survival in MCF-7 cells exposed to paclitaxel. On the other hand, the lack of p21 induction by paclitaxel in NIH-OVCAR-3 cells was associated with a prolonged mitotic block and cell death by apoptosis.
Results
Relationship between increase in p21 and cell cycle arrest in mitosis induced by paclitaxel As shown in Figure 1 , paclitaxel (50 nM) led to a time dependent increase in levels of p21 protein in MCF-7 cells. In line with the ®ndings of Blagosklonny et al. (1995) , we found that levels increased between 24 and 36 h after paclitaxel and remained elevated at least until 72 h. In order to study the role of p21 in cellular responses to paclitaxel, we ®rst examined the sensitivity of MCF-7 cells to paclitaxel using a clonogenic assay. The IC 50 determined following continuous exposure of this cell line to paclitaxel was 0.9+0.1 nM (mean+s.d. of three dierent experiments). Paclitaxel completely blocked MCF-7 cell proliferation and induced a timedependent decrease in MCF-7 cell number (Figure 2a) . The decrease in cell number is preceded by a time ( Figure 2b ) and a dose-dependent ( Figure 2c ) increase in the number of MCF-7 cells arrested with a 4N DNA content. Cell cycle block ( Figure 2b ) was observed 12 h after addition of paclitaxel, whereas the increase in p21 protein levels occurred at 24 h and was maximal 36 h after addition of this drug (Figure 1 ), suggesting that the increase in p21 is a consequence of the cell cycle arrest. In an attempt to con®rm this causality, we examined the in¯uence of paclitaxel on NIH-OVCAR-3 cells, a p21-negative cell line . Paclitaxel was cytotoxic in this cell line (IC 50 =0.7+0.2 nM). Flow cytometric analysis of DNA indicated that paclitaxel induced a time ( Figure  2b ) and dose-dependent (Figure 2c ) accumulation of cells with a G2/M DNA content, leading to a very rapid decline in cell number (Figure 2a ). Western blot analysis of p21 content indicated that p21 was undetectable in NIH-OVCAR-3 cells either at the basal level or at various times (from 6 ± 72 h) after addition of paclitaxel (50 nM) (data not shown). Taken together, these results indicate that the increase in p21 occurs after cell cycle arrest and is not required for paclitaxel-induced accumulation of cells with a G2/M DNA content.
We next investigated whether the increase in p21 was directly due to paclitaxel or whether it might have re¯ected an alteration in cell cycle distribution. Cells were thus analysed by¯ow cytometry for both DNA and p21 content. Figure 3 represents the expression of p21 in control and paclitaxel-treated MCF-7 cells as a function of their position in the cell cycle. In the control cell population (Figure 3a) , 47% of cells were in G1 and 14% of cells were in G2/M phase; 7% of the G1 cells and 19% of the G2/M cells were p21 positive. Treatment of MCF-7 cells with paclitaxel (50 nM, 24 h) not only led to an accumulation of cells in the G2/M phase (89% compared to 14% in control cells) but also increased p21 content in this particular phase (Figure 3b ). Indeed, after paclitaxel addition 68% of G2/M cells expressed p21 compared to 19% of control G2/M cells. An increase in p21 was also found in the small proportion of cells remaining in the G1 phase after paclitaxel treatment. The paclitaxelinduced increase in p21 was therefore assumed to be speci®c and not dependent on accumulation of cells in the G2/M phase.
Mitotic exit after paclitaxel treatment
It is generally thought that the mitotic block induced by low concentrations of paclitaxel is transient (Kung et al., 1990) . Cells exit mitosis without completion of late mitotic events such as chromosome segregation and cytokinesis and progress to an interphase-like state (Andreassen and Margolis, 1994; Jordan et al., 1996) . Consequently, paclitaxel-treated cells displaying a G2/ M DNA content correspond either to cells arrested in mitosis or to those that have undergone abnormal mitosis without cytokinesis. In order to determine whether p21 was increased by paclitaxel in abnormal mitosis or in G1 cells we analysed p21 expression by indirect immuno¯uorescence microscopy. After 36 h exposure to 50 nM paclitaxel, numerous MCF-7 cells were blocked in an abnormal mitotic stage (Figure 4c ). We also observed cells with decondensed chromatin and micronuclei (Figure 4e ). p21 immunoreactivity was markedly increased by paclitaxel in cells presenting either abnormal mitosis compared to cells in normal mitosis, or micronuclei ( Figure 4d , b and f respectively), suggesting that the paclitaxel-induced p21 starts to accumulate before the accumulation of cells in G1 of the subsequent cell cycle. The mitotic index, assessed by the presence of condensed chromatin, peaked 24 h after addition of paclitaxel (50 nM) in both MCF-7 and NIH-OVCAR cells ( Figure 5 ). However, the fall in mitotic index occurred 48 h and 72 h after addition of paclitaxel in MCF-7 and NIH-OVCAR-3 cells respectively ( Figure 5 ), indicating that MCF-7 cells exit abnormal mitosis earlier than NIH-OVCAR-3 cells do.
We measured p34 cdc2 activity at dierent times after addition of paclitaxel in both MCF-7 and NIH-OVCAR-3 cells. As shown in Figure 6 , p34 cdc2 activity increased after paclitaxel treatment and reached a maximal level after 24 h in MCF-7 cells. In NIH-OVCAR-3 cells, the maximal activity was reached by 6 h and stayed high until 48 h. A decline in p34 cdc2 activity was observed 36 h after paclitaxel in MCF-7 cells, whereas it was observed after 72 h in NIH-OVCAR-3 cells ( Figure 6 ).
p21 increases in p34 cdc2 complex after paclitaxel treatment
The inhibition of p34 cdc2 activity was concomitant with the increase in total p21 protein in MCF-7 cells, whereas in NIH-OVCAR-3 cells, devoid of p21, p34 Figure 1 Western blot analysis of p21 protein after paclitaxel treatment in MCF-7 cells. Total cell lysates were prepared at various times after addition of 50 nM paclitaxel, 100 mg of total cell protein were separated by SDS ± PAGE, transferred to nitrocellulose and Western blotting was carried out using antibody against p21. To control for the amount of protein in each line, the same blot was probed with anti-actin mAb , 1993) . Forty-eight hours after treatment with paclitaxel (50 nM), numerous MCF-7 and NIH-OVCAR-3 cells exhibited signs of abnormal mitosis ( Figure 8A ). At this time point, apoptotic ®gures characterized by chromatin condensation (DAPI staining, Figure 8A , a) and DNA fragmentation (TUNEL staining, Figure 8A , d) were detected in NIH-OVCAR-3 cells. We observed a time-dependent increase in paclitaxel-induced apoptosis in NIH-OVCAR-3 cells, whereas paclitaxel failed to increase signi®cantly the basal level of apoptosis in MCF-7 cells ( Figure 8A and B). These results indicate that a delay in mitotic exit was linked with induction of apoptotic cell death in NIH-OVCAR-3 cells.
In¯uence of antisense-p21 on cell survival after paclitaxel treatment
Our present ®ndings suggest that p21 participates in mitotic exit after paclitaxel treatment and may thus play a role in the inhibition of apoptosis induced by this drug. In order to assess the possible role of the elevation of p21 in paclitaxel sensitivity, we measured paclitaxel cytotoxicity in the presence of a p21-antisense oligonucleotide. Incubation of MCF-7 cells with this p21 antisense oligonucleotide impaired the ability of paclitaxel (50 nM for 36 h) to raise levels of p21 ( Figure 9a ). We measured clonogenic survival in response to paclitaxel treatment in the presence of p21 sense or antisense oligonucleotides. As shown in Figure  9b , only the p21 antisense oligonucleotide signi®cantly increased the cytotoxicity of paclitaxel. has been shown to be implicated in the G1 checkpoint (Gartel et al., 1996) . The results presented here indicate that p21 may play a role in the mitotic checkpoint. After mitotic spindle damage induced by paclitaxel, the rise in levels of p21 was found to be linked to the inhibition of p34 cdc2 activity and exit from abnormal mitosis. Inhibition of p34 cdc2 activity was concomitant with the association of p21 with the p34 cdc2 protein complex. Inhibition of paclitaxelinduced p21 expression in MCF-7 cells was associated with a signi®cant increase in paclitaxel cytotoxicity, whereas in NIH-OVCAR-3 cells, which are devoid p21, paclitaxel induced apoptosis. This indicated that p21 may function in a pathway that senses the consequence of an abortive mitosis after mitotic spindle damage.
p21 is involved in p53 G1 and G2 checkpoints, but is not thought to be required for the p53 mitotic spindle checkpoint (Deng et al., 1995) . However, it has been shown that drugs which alter microtubule function increase p21 expression (Tishler et al., 1995; Blagosklonny et al., 1995) . Paclitaxel, which stabilizes microtubules and prevents depolymerization of microtubules (Schi et al., 1979 (Schi et al., , 1980 ), induces an increase in level of p21 protein, mediated by c-raf-1 activation, in both p53-wild type and p53-null cells (Blagosklonny et al., 1995) . However, this paclitaxel-induced p21 expression has not been seen in all cell lines (Tishler , 1997) . The exact role of p21 in the cellular response to mitotic spindle damage thus remains to be elucidated. We found here that increase in p21 and modi®cations of cell cycle progression were observed at the same paclitaxel concentrations. These concentrations were higher from those required to inhibit MCF-7 cell survival. The duration of drug exposure was longer for paclitaxel cytotoxic eect than for p21 induction or cell cycle eect. Indeed, it has been shown that increasing the time of exposure to paclitaxel results in a marked increase in cytotoxicity (Liebmann et al., 1993) . According to this author, we found that a similar dose of paclitaxel (1 nM) induced a cytotoxic eect which depends on the duration of paclitaxel treatment. After 8 days of paclitaxel treatment a 50% cell survival was observed for a paclitaxel concentration of 0.9 nM whereas an 80% cell survival was found after a 16 h exposure (Figure 9b) . A time-dependent intracellular accumulation of paclitaxel could account for these variations (Jordan et al., 1993) . Paclitaxel treatment of MCF-7 cells not only leads to an accumulation of cells with a G2/M DNA content, but also increases p21 in this phase of the cell cycle, suggesting that the increase in p21 may be the cause or the consequence of the paclitaxel-induced cell cycle block. The time course of p21 accumulation in MCF-7 cells indicated that p21 protein levels became elevated after accumulation of cells with a G2/M DNA content. Furthermore, in NIH-OVCAR-3 cells, paclitaxel failed to induce expression of p21, whereas a low dose of this compound elicited an accumulation of cells in the G2/M phase of the cell cycle. These observations indicate that p21 is not involved in paclitaxel-induced mitotic arrest of the cell cycle, but is a consequence of it. It has been demonstrated that the mitotic block induced by paclitaxel is transient; cells progress into an interphase state without completing anaphase, telophase and cytokinesis (Jordan et al., 1996) . The mitotic spindle fails to segregate the sister chromatids resulting in the formation of a nuclear membrane around a (Long and Fairchild, 1994) . Cytometric analysis of DNA content indicated that MCF-7 and NIH-OVCAR-3 cells harbor G2/M DNA for 72 h after addition of paclitaxel. However, the measurement of the mitotic index showed that MCF-7 cells and NIH-OVCAR-3 cells exit mitosis 48 h and 72 h respectively, after exposure to paclitaxel, confirming that exit from mitotis occurs without cell division (Jordan et al., 1996; Long and Fairchild, 1994) and at dierent times in dierent cell types (Kung et al., 1990) . Cell doubling times are 40 h and 44 h respectively for MCF-7 and NIH-OVCAR-3 cells (Figure 2a) , a dierence of 4 h in their cell cycle time could not explain the dierence in the variation of mitotic index observed between these two cell lines. We found that, after mitotic exit, MCF-7 cells entered a subsequent G1 phase characterized by formation of micronuclei, whereas apoptotic cell death occurred in the NIH-OVCAR-3 cells. MCF-7 cells accumulated as G1 4N cells without additional DNA synthesis, indeed only 1.5% of cells presented a DNA content44N. This result agrees well with those peviously reported on HeLa adenocarcinoma cells (Jordan et al., 1996) but diers from those reported for SV40 transformed rat normal embryo ®broblasts which accumulated as 8N cells (Trielli et al., 1996) . In normal cells, paclitaxel bypasses the mitotic block leading to an accumulation of cells in the G1 phase of the next cell cycle; the arrest in G1 being associated with induction of p21 (Wahl et al., 1996) . The strong p21 staining observed in micronuclei from paclitaxel-treated MCF-7 cells indicated that this also occurred in this tumoral cell line. However, the paclitaxel-induction of p21 in MCF-7 cells was detected prior to the decrease in mitotic index, and, furthermore, p21 staining was also strong in MCF-7 cells arrested in abnormal mitosis. These observations suggest that the paclitaxel-induced increase in p21 plays a dierent role in tumoral than in normal cells (Wahl et al., 1996) . The activity of p34 cdc2 peaks in mitosis and exit from mitosis requires its inactivation through cyclin B degradation (review in Draetta, 1990) . However, little is known about the regulation of p34 cdc2 activity when the exit from mitosis is abnormal, in the absence of anaphase, telophase and cytokinesis. Mitotic exit and inhibition of p34 cdc2 activity are both dependent on the state of assembly of microtubules (Andreassen and Margolis, 1994) . In MCF-7 cells, inhibition of p34 cdc2 activity reached a peak 36 h after addition of paclitaxel. At this time, no variations in the level of p34 cdc2 and only a slight decrease in cyclin B protein level were observed (data not shown), indicating that the total inhibition of p34 cdc2 activity in this cell line was not due to any alteration in levels of p34 cdc2 or cyclin B protein. Our results in MCF-7 cells pointed to a link between the increase in p21 and the inhibition of p34 cdc2 activity 36 h after paclitaxel treatment. p21 may thus inhibit p34 cdc2 by binding to it. Indeed, p21 is a universal inhibitor of CDK, and it inhibits G1 CDK with a Ki value of 0.5 ± 15 nM, although it is less eective toward the p34 cdc2 / cyclin B complex with a Ki of 400 nM . Although, in vitro, the anity of p21 for p34 cdc2 / cyclinB complex is low, in vivo, other cellular proteins may well increase the anity of p21 for this complex. It has been shown recently that overexpression of p21 in astrocytoma cells leads to an inhibition of p34 cdc2 activity due to a decrease in levels of p34 cdc2 protein (Chen et al., 1996) . In addition, irradiation leads to an increase in the levels of p21 associated with the p34 cdc2 / cyclin B complex in human ®broblasts (Levedakou et al., 1995) . When p34 cdc2 immunoprecipitates from MCF-7 cells were analysed by Western blotting for association with p21, we observed a marked increase in the amount of p21 associated with the p34 cdc2 /cyclinB complex concomitant with the inhibition of p34 cdc2 activity. This suggests that p21 participates directly in the regulation of mitotic exit after micotubule damages induced by paclitaxel, via an action on the p34 cdc2 /cyclinB complex. This was supported by the ®ndings that paclitaxel treatment of NIH-OVCAR-3 cells failed to induce p21 and that p34 cdc2 activity remained at a high level for at least 48 h.
The exact role of a sustained mitotic arrest or mitotic slippage in the cellular response to paclitaxel is unclear. In normal cells, it has been shown that the increased arrest in mitosis and apoptosis is linked to loss of p53 (Wahl et al., 1996) . In tumoral cells, paclitaxel-induced apoptosis has been associated with mitotic block and abnormal mitotic exit (Jordan et al., 1996) . We found here that the delay in mitotic exit was associated with apoptosis in the NIH-OVCAR-3 cell line. Several studies have indicated that p34 cdc2 activity mediates apoptotic cell death (Shi et al., 1994; Shimizu et al., 1995) , and it has been suggested that p34 cdc2 plays a role in paclitaxel induced-apoptosis (Donaldson et al., 1994) . In the present study, we found that a prolonged activation of p34 cdc2 in the absence of p21 expression was associated with apoptosis, whereas apoptosis did not occur when p21 was elevated enabling an earlier inhibition of p34 cdc2 activity. This argues in favor of a repressor role for p21 in inhibiting paclitaxel-induced apoptosis mediated by p34 cdc2 . Several studies have shown that p21 acts as a survival factor (Poluha et al., 1996; Polyak et al., 1996; Waldman et al., 1996; Wang and Walsh, 1996) . We found that inhibition of p21 expression using a p21 antisense oligonucleotide led to a signi®cant increase in paclitaxel cytotoxicity in MCF-7 cells. This is consistent with reports showing that the decrease in p21 expression after PGA2 treatment promotes MCF-7 apoptosis. The implication of p21 as a repressor of the paclitaxel apoptotic signal is now under investigation in our laboratory.
Materials and methods

Cell culture
The human ovarian carcinoma cell line NIH-OVCAR-3 (ATCC) and the human breast adenocarcinoma cell line MCF-7 (ATCC) were grown in RPMI-1640 medium supplemented with 5% fetal calf serum (FCS), 2 nM glutamine, 50 mg/ml gentamycin in humidi®ed 5% CO 2 / 95% air at 378C. Insulin (5 mg/ml) was added to the MCF-7 culture medium.
Cytotoxicity assay
Cytotoxicity was assessed using a clonogenic assay. (Draetta and Beach, 1988) were used for the Western blot and immunoprecipitation experiments. Mouse monoclonal antibodies to p21 and actin proteins were purchased from Oncogene Research and Euromedex, respectively.
Antisense oligonucleotides
Phosphorothioate oligodeoxynucleotides (2 mg/ml) and lipofectin (GIBCO BRL) (10 mg/ml) were incubated at 378C for 15 min. The oligonucleotide-lipofectin mixture was diluted with serum containing medium and added to the cells in presence or absence of 50 nM paclitaxel for various time. We used antisense oligonucleotides based on the p21 coding sequence Asp21 which is complementary to the region of the initiation codon (5'-TCC CCA GCC GGT TCT GAC AT-3') and the sense p21 (Sp21) as control (5'-ATG TCA GAA CCG GCT GGG GA-3'). These oligonucleotides were purchased from Eurobio, Les Ullis, France).
Flow cytometry
Eect of paclitaxel on cell cycle parameters Asynchronous MCF-7 and NIH-OVCAR-3 cells were plated at a density of 10 4 cells/cm 2 . On the following day, paclitaxel was added. At the times indicated, cells were washed in PBS then treated with 0.25% trypsin-0.02% EDTA and harvested after removal of trypsin. After centrifugation (300 g, 10 min), the pelleted cells were ®xed in 80% ethanol overnight at 7208C. The samples were centrifuged, washed with PBS and resuspended in 10 mg/ml of propidium iodide (PI) (Sigma) and 0.1% RNAse A (Sigma) in PBS. After a 15 min incubation at 378C, cell cycle phase distribution was determined by analytical¯ow cytometry using LYSIS II software (Becton Dickinson).
p21 Monoclonal antibody and PI staining Cells were rinsed with PBS and suspended in 80% ethanol overnight at 7208C as described by Darzynkiewicz et al. (1994) . The samples were then centrifuged, washed with PBS and treated with 0.25% Triton in PBS for 5 min on ice. After addition of PBS and centrifugation, the cells were incubated overnight at 48C in the presence of the mouse monoclonal antibody to human p21 diluted 1 : 20 in PBS containing 1% bovine serum albumin (BSA). Cells were washed and incubated with a¯uorescein 5-isothiocyanate (FITC)-conjugated goat anti-mouse IgG antibody (Sigma) diluted 1 : 100 in PBS containing 1% BSA. Cells were washed and resuspended in 10 mg/ml of propidium iodide (PI) and 0.1% RNAse A in PBS and incubated for 15 min prior to FACScan analysis. The control was prepared in an identical way except that an isotype-speci®c antibody (Mouse IgG1 from Sigma) was used instead of the p21 antibody. Cellular¯uorescence was measured in a FACScan¯ow cytometer (Becton Dickinson). The red (PI) and green (FITC)¯uorescence from each cell were separated and quantitated by the FACScan using the standard optics and LYSIS II software (Becton Dickinson).
Western blotting, immunoprecipitation and kinase activity
Cells were washed with PBS and lysed in ice-cold lysis buer (Tris-HCl pH 7.5, 250 mM NaCl, 5 mM EDTA, 1 mM DTT, 0.1% Triton, 50 mM sodium¯uoride, 1 mM sodium orthovanadate, 100 mg/ml PMSF and TPCK, 50 mg/ml TLCK, 1 mg/ml leupeptin, pepstatin and aprotinin). Lysates were clari®ed by centrifugation. For Western blot analysis, 100 mg of protein were resolved by SDSpolyacrylamide gel electrophoresis and transferred to nitrocellulose membranes by semi-dry blotting. The membranes were hybridized with p34 cdc2 , cyclin B and p21 antibodies. The blot was probed with actin antibody for equal loading control.
For immunoprecipitation as for kinase activity determination, rabbit polyclonal p34 cdc2 antibody was added to 1 mg of precleared cell lysates and incubated at 48C for 2 h on a rotating platform. Immune complexes were recovered with protein A-agarose (Pharmacia) and washed three times with lysis buer. For immunoprecipitation, immune complexes were separated on 15% SDS-polyacrylamide gels as described above and a mouse monoclonal p21 antibody or a rabbit polyclonal p34 cdc2 were used for immunoblot analysis. For p34 cdc2 kinase activity, beads were washed again with kinase assay buer (50 mM Tris-HCl pH 8, 10 mM MgCl 2 , 1 mM dithiothreitol). Phosphorylation of histone H1 was measured by incubating the beads with 30 ml of a reaction mixture containing 10 mM ATP (Boehringer Mannheim Corp.), 5 mCi [ 32 P]g-ATP (3000 Ci/ mmol; New England Nuclear) and 2 mg histone H1 (Boehringer Mannheim Corp.) in kinase assay buer for 30 min at 308C. The reaction was stopped by boiling the samples in Laemmli SDS sample buer for 5 min and samples were resolved by 12% SDS ± PAGE. The gels were dried and subjected to autoradiography.
Immuno¯uorescence staining DAPI staining Cells were grown on glass coverslips, washed once with PBS and ®xed in PBS/3.7% formaldehyde for 15 min at 48C. Cells were permeabilized in PBS/ 0.25% Triton X-100 for 5 min at room temperature and methanol 100% for 10 min at 7208C. DNA was stained by incubating the cells with a 0.1 mg/ml solution of DAPI in PBS. Coverslips were then mounted on glass slides with Mowiol (Calbiochem). The cells were examined under a Zeiss Axiophot photomicroscope using a Neo¯uar 406 lens. For the quantitative analysis of apoptosis, a minimum of 1000 nuclei were counted for each experiment.
p21 staining Fixed and permeabilized cells were ®rst incubated in PBS/BSA 1% for 15 min at room temperature and then incubated overnight at 48C with a monoclonal anti-p21 antibody (dilution 1 : 100) in 1% PBS-BSA. After three washes in 1% PBS-BSA, cells were incubated with Texas Red-conjugated sheep anti-mouse antibody (dilution 1 : 200; Amersham) for 1 h at room temperature. Coverslips were washed and incubated for 10 min at room temperature with a 0.1 mg/ml solution of DAPI in PBS. The cells were examined under a Zeiss Axiophot photomicroscope using a Neo¯uar 1006 lens and photographs were taken on Kodak Tmax 400 ®lm.
TUNEL assay Detection of apoptosis by immunofluorescence staining and using the ability of terminal deoxynucleotidyl transferase (TdT) to incorporate biotindUTP to 3'OH-ends of DNA breaks was carried out as described elsewhere (Lafon et al., 1996) . Brie¯y, after ®xation and permeabilization, cells were incubated with TdT and biotin-dUTP for 1 h at 378C and counterstained with FITC-conjugated streptavidin at room temperature in the dark for 30 min. Cells were examined using a Neo¯uar 406 lens and photographs were taken as described above.
